BiotechTube

Evorpacept (ALX148) + Cetuximab + Pembrolizumab

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Microsatellite Stable Metastatic Colorectal Cancer

Conditions

Microsatellite Stable Metastatic Colorectal Cancer

Trial Timeline

Jul 28, 2022 → Mar 1, 2026

NCT ID
NCT05167409

About Evorpacept (ALX148) + Cetuximab + Pembrolizumab

Evorpacept (ALX148) + Cetuximab + Pembrolizumab is a phase 2 stage product being developed by Eli Lilly for Microsatellite Stable Metastatic Colorectal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05167409. Target conditions include Microsatellite Stable Metastatic Colorectal Cancer.

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05167409Phase 2Active

Competing Products

11 competing products in Microsatellite Stable Metastatic Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
25
grapiprant + grapiprant and pembrolizumabMerckPhase 1
29
Bevacizumab + Capecitabine + PembrolizumabMerckPhase 2
35
MK-3475 + INCB024360MerckPhase 1/2
32
AMG 436AmgenPhase 1
36
Nivolumab + IpilimumabBristol Myers SquibbPhase 2
39
Nivolumab + IpilimumabBristol Myers SquibbPhase 2
31
Copanlisib + NivolumabBristol Myers SquibbPhase 1/2
32
Ipilimumab + Nivolumab + Cobimetinib + Daratumumab + BMS-986016Bristol Myers SquibbPhase 2
35
Nivolumab + RelatlimabBristol Myers SquibbPhase 2
35
Balstilimab + BotensilimabAgenusPhase 2
32